Migraine Drugs Market Growth Overview Along with Company Profiles Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Johnson & Johnson, Merck & Co., and Pfizer Inc.

Migraine Drugs Market size was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period. Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea, and even disturbed vision in some cases.

Surge in awareness about migraine treatment and prevention across the globe is anticipated to significantly drive the growth of the migraine drugs market. Furthermore, rise in female population worldwide is the key factor that augments the market growth.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/2811

Increase in prevalence of migraine, rapid rise in female population, and surge in awareness among patients for migraine treatment & prevention drive the growth of the global migraine drugs market. However, side effects of migraine drugs are expected to limit the market growth. Conversely, emerging new therapies/drugs for migraine treatment and growth opportunities in the emerging nations are expected to present opportunities for the market growth during the forecast period.

By type, abortive medicines accounted for more than three-fourths share of the global migraine drugs market in 2017. Furthermore, by route of administration, the oral segment is anticipated to grow at the highest rate of 3.4% during the forecast period.

KEY FINDINGS OF THE STUDY

• North America occupied two-fifths share of the global migraine drugs market.
• Oral is anticipated to grow with the highest CAGR throughout the forecast period.
• Europe is anticipated to occupy more than one-fourth market share of the global migraine drugs market by 2025.
• Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

North America was the leading revenue contributor to the global market in 2017, owing to surge in demand for better healthcare along with effective government reforms for awareness towards migraine & its prevention. However, Asia-Pacific is expected to grow at the highest CAGR of 4.4% from 2018 to 2025, due to improvements in healthcare infrastructure and rise in demand for better healthcare facilities.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/2811

The report provides an extensive competitive analysis and profiles of the key market players such as Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Johnson & Johnson, Merck & Co., and Pfizer Inc. The other players in the value chain (not included in the report) include Novartis International AG, Teva Pharmaceutical Industries Limited, and Sanofi SA.

Table Of Content

Chapter: 1: INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.3.1. List of players profiled in the report
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective

Chapter: 3: MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2016-2018
3.2.3. Market share analysis, 2017
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Increase in prevalence of migraine
3.3.1.2. Growth in female population
3.3.1.3. Rise in awareness among patients towards migraine treatment & prevention
3.3.2. Restraints
3.3.2.1. Side effects of migraine drugs
3.3.3. Opportunities
3.3.3.1. Emerging migraine therapies
3.3.3.2. Growth opportunities in the emerging economies
3.3.4. Impact analyses

Access Full Summery @ https://www.alliedmarketresearch.com/press-release/migraine-drugs-market.html

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.